You just read:

AcelRx Pharmaceuticals' ARX-04 Phase 3 Trial Met its Primary Endpoint, Reduced Pain Intensity in ER Patients with Moderate-to-Severe Acute Pain

News provided by

AcelRx Pharmaceuticals, Inc.

15 Aug, 2016, 07:00 ET